Tirdzniecība ImmuCell - ICCC CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.66 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 4.64 |
| Atvērt* | 4.5 |
| Izmaiņas par 1 gadu* | -45.12% |
| Dienas Diapazons* | 4.5 - 4.97 |
| 52 ned Diapazons | 4.68-10.96 |
| Vidējais apjoms (10 dienas) | 11.32K |
| Vidējais apjoms (3 mēneši) | 149.79K |
| Tirgus Kapitalizācija | 37.73M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 7.75M |
| Ieņēmumi | 18.57M |
| EPS | -0.32 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.70 |
| Nākamās Peļņas Datums | May 10, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | 4.59 | 0.00 | 0.00% | 4.59 | 4.69 | 4.59 |
| Mar 16, 2023 | 4.68 | -0.10 | -2.09% | 4.78 | 4.97 | 4.46 |
| Mar 15, 2023 | 4.78 | -0.06 | -1.24% | 4.84 | 4.85 | 4.78 |
| Mar 14, 2023 | 4.98 | -0.06 | -1.19% | 5.04 | 5.26 | 4.97 |
| Mar 13, 2023 | 4.95 | -0.31 | -5.89% | 5.26 | 5.26 | 4.55 |
| Mar 10, 2023 | 5.17 | -0.09 | -1.71% | 5.26 | 5.35 | 4.78 |
| Mar 9, 2023 | 5.43 | -0.03 | -0.55% | 5.46 | 5.94 | 5.16 |
| Mar 8, 2023 | 5.45 | -0.53 | -8.86% | 5.98 | 6.03 | 5.41 |
| Mar 7, 2023 | 5.64 | -0.23 | -3.92% | 5.87 | 5.87 | 5.35 |
| Mar 6, 2023 | 5.50 | -0.35 | -5.98% | 5.85 | 5.88 | 5.17 |
| Mar 3, 2023 | 5.56 | -0.18 | -3.14% | 5.74 | 5.84 | 5.55 |
| Mar 2, 2023 | 5.52 | 0.20 | 3.76% | 5.32 | 5.56 | 5.16 |
| Mar 1, 2023 | 5.55 | -0.01 | -0.18% | 5.56 | 5.62 | 5.45 |
| Feb 28, 2023 | 5.60 | -0.04 | -0.71% | 5.64 | 5.68 | 5.52 |
| Feb 27, 2023 | 5.69 | 0.01 | 0.18% | 5.68 | 5.79 | 5.54 |
| Feb 24, 2023 | 5.88 | -0.04 | -0.68% | 5.92 | 6.06 | 5.75 |
| Feb 23, 2023 | 6.19 | -0.32 | -4.92% | 6.51 | 6.51 | 5.88 |
| Feb 22, 2023 | 6.53 | -0.10 | -1.51% | 6.63 | 6.65 | 6.28 |
| Feb 21, 2023 | 6.89 | 0.15 | 2.23% | 6.74 | 6.89 | 6.67 |
| Feb 17, 2023 | 6.84 | 0.18 | 2.70% | 6.66 | 6.89 | 6.66 |
ImmuCell Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 9.54396 | 10.4311 | 10.9863 | 13.7229 | 15.3422 | 19.243 |
| Ienākumi | 9.54396 | 10.4311 | 10.9863 | 13.7229 | 15.3422 | 19.243 |
| Cost of Revenue, Total | 4.12327 | 5.20973 | 5.79239 | 6.98315 | 8.47938 | 10.587 |
| Bruto Peļņa | 5.42069 | 5.22136 | 5.19391 | 6.73972 | 6.86282 | 8.65593 |
| Kopējie Darbības Izdevumi | 8.65376 | 10.6739 | 12.4329 | 14.6768 | 15.8796 | 18.9856 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 3.28616 | 3.41764 | 3.82386 | 4.00602 | 3.88855 | 4.23003 |
| Pētniecība un Attīstība | 1.24434 | 2.04656 | 3.51662 | 3.68761 | 4.35463 | 4.16852 |
| Darbības Izdevumi | 0.8902 | -0.24285 | -1.44657 | -0.95391 | -0.53744 | 0.25739 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.10704 | -0.20166 | -0.41348 | -0.31351 | -0.29047 | -0.29555 |
| Citi, Neto | -0.02485 | 0.00603 | 0 | -0.16505 | 0 | |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 0.75832 | -0.43848 | -1.86005 | -1.26741 | -1.03225 | -0.06913 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 0.50845 | -0.23915 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 0.50845 | -0.23915 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Neto Ienākumi | 0.50845 | -0.16815 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 0.50845 | -0.23915 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 0.50845 | -0.16815 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Atšķaidīšanas Iestāstīšana | 0.0119 | |||||
| Atšķaidītie Neto Ienākumi | 0.52035 | -0.16815 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Atšķaidītie Ienākumi par Akcijām | 4.33623 | 4.94921 | 5.48615 | 6.81896 | 7.21333 | 7.59229 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.12 | -0.04832 | -0.42319 | -0.19 | -0.1417 | -0.01031 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.12 | -0.04832 | -0.50612 | -0.19 | -0.21411 | -0.00766 |
| Ārkārtas Posteņi Kopā | 0.071 | |||||
| Neparedzēti Izdevumi (Ienākumi) | -0.7 | -0.84292 | ||||
| Gain (Loss) on Sale of Assets | -0.0393 | -0.03096 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 4.10715 | 4.54181 | 5.15017 | 5.44384 | 5.99968 |
| Ienākumi | 4.10715 | 4.54181 | 5.15017 | 5.44384 | 5.99968 |
| Cost of Revenue, Total | 2.50496 | 2.46749 | 2.73147 | 2.88313 | 2.89646 |
| Bruto Peļņa | 1.60219 | 2.07432 | 2.4187 | 2.56071 | 3.10322 |
| Kopējie Darbības Izdevumi | 4.48177 | 4.3263 | 4.87908 | 5.29843 | 5.2067 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 0.94575 | 0.85871 | 1.10012 | 1.32546 | 1.2743 |
| Pētniecība un Attīstība | 1.03106 | 1.00011 | 1.0475 | 1.08985 | 1.03594 |
| Darbības Izdevumi | -0.37462 | 0.21551 | 0.27109 | 0.14541 | 0.79298 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.07668 | -0.0744 | -0.07301 | -0.07147 | -0.06802 |
| Gain (Loss) on Sale of Assets | 0.01 | 0 | -0.04228 | 0.00132 | 0.011 |
| Citi, Neto | 0 | 0.00085 | |||
| Neto Ienākumi Pirms Nodokļu Nomaksas | -0.4413 | 0.14111 | 0.15581 | 0.07526 | 0.73681 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -0.4413 | 0.14111 | 0.14776 | 0.07413 | 0.73567 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -0.4413 | 0.14111 | 0.14776 | 0.07413 | 0.73567 |
| Neto Ienākumi | -0.4413 | 0.14111 | 0.14776 | 0.07413 | 0.73567 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -0.4413 | 0.14111 | 0.14776 | 0.07413 | 0.73567 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -0.4413 | 0.14111 | 0.14776 | 0.07413 | 0.73567 |
| Atšķaidītie Neto Ienākumi | -0.4413 | 0.14111 | 0.14776 | 0.07413 | 0.73567 |
| Atšķaidītie Ienākumi par Akcijām | 7.21944 | 7.76106 | 7.82029 | 7.74351 | 7.78947 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.06113 | 0.01818 | 0.01889 | 0.00957 | 0.09444 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.06251 | 0.01818 | 0.02402 | 0.00941 | 0.09303 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 14.3481 | 7.50723 | 6.42084 | 13.189 | 12.157 | 16.2649 |
| Nauda un Īstermiņa Ieguldījumi | 10.6244 | 3.79881 | 2.52105 | 8.77405 | 7.94643 | 10.1855 |
| Nauda un Ekvivalenti | 5.15034 | 3.79881 | 2.52105 | 6.29329 | 6.94994 | 10.1855 |
| Īstermiņa Ieguldījumi | 5.47401 | 0 | 2.48075 | 0.9965 | 0 | |
| Debitoru Parādu Kopsumma, Neto | 0.99239 | 1.34402 | 0.9323 | 1.6777 | 1.86442 | 2.72071 |
| Accounts Receivable - Trade, Net | 0.99239 | 1.34402 | 0.9323 | 1.63717 | 1.7968 | 2.69423 |
| Total Inventory | 2.1269 | 2.04973 | 2.33167 | 2.51826 | 2.09251 | 3.08997 |
| Prepaid Expenses | 0.60448 | 0.31467 | 0.63582 | 0.21823 | 0.25284 | 0.26871 |
| Other Current Assets, Total | 0 | 0.0008 | 0.0008 | 0 | ||
| Total Assets | 24.6972 | 34.299 | 32.7308 | 38.6918 | 40.3496 | 44.4657 |
| Property/Plant/Equipment, Total - Net | 9.84629 | 26.0697 | 26.0275 | 25.2657 | 27.9753 | 28.0027 |
| Goodwill, Net | 0.09556 | 0.09556 | 0.09556 | 0.09556 | 0.09556 | 0.09556 |
| Intangibles, Net | 0.17194 | 0.15283 | 0.13373 | 0.11462 | 0.09552 | 0.07642 |
| Long Term Investments | 0 | |||||
| Other Long Term Assets, Total | 0.23527 | 0.47365 | 0.05316 | 0.02688 | 0.02617 | 0.02612 |
| Total Current Liabilities | 2.05889 | 2.064 | 2.56501 | 2.49536 | 2.21108 | 2.53447 |
| Payable/Accrued | 1.89176 | 1.72327 | 1.22066 | |||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.13327 | 0.31663 | 1.34435 | 1.27479 | 0.76034 | 0.81221 |
| Other Current Liabilities, Total | 0.03386 | 0.0241 | 0 | 0.17511 | 0.13748 | 0.20122 |
| Total Liabilities | 4.97504 | 10.704 | 10.9865 | 9.70056 | 12.0834 | 11.8888 |
| Total Long Term Debt | 2.87881 | 8.63902 | 8.42149 | 7.14668 | 8.73715 | 8.32712 |
| Long Term Debt | 2.87881 | 8.63902 | 8.42149 | 7.14668 | 8.73715 | 8.32712 |
| Other Liabilities, Total | 0.03735 | 0.001 | 0 | 0.05853 | 1.13517 | 1.02716 |
| Total Equity | 19.7221 | 23.5949 | 21.7443 | 28.9913 | 28.2662 | 32.5769 |
| Common Stock | 0.50448 | 0.56627 | 0.56627 | 0.7299 | 0.7299 | 0.78142 |
| Additional Paid-In Capital | 18.5264 | 22.4582 | 22.6956 | 31.1319 | 31.3721 | 35.6924 |
| Retained Earnings (Accumulated Deficit) | 1.14712 | 0.97897 | -1.3427 | -2.63829 | -3.6604 | -3.73869 |
| Treasury Stock - Common | -0.43194 | -0.40788 | -0.20495 | -0.18834 | -0.17539 | -0.15817 |
| Other Equity, Total | -0.0239 | -0.00064 | 0.03016 | -0.0439 | 0 | |
| Total Liabilities & Shareholders’ Equity | 24.6972 | 34.299 | 32.7308 | 38.6918 | 40.3496 | 44.4657 |
| Total Common Shares Outstanding | 4.84739 | 5.4762 | 5.56896 | 7.21292 | 7.21884 | 7.74186 |
| Property/Plant/Equipment, Total - Gross | 34.8769 | 39.6407 | 41.996 | |||
| Accumulated Depreciation, Total | -9.61119 | -11.6653 | -13.9933 | |||
| Accounts Payable | 0.57218 | 0.60235 | 0.74504 | |||
| Accrued Expenses | 0.47328 | 0.71091 | 0.776 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 11.8098 | 15.5321 | 16.0755 | 16.2649 | 18.2991 |
| Nauda un Īstermiņa Ieguldījumi | 6.80665 | 10.7006 | 10.4958 | 10.1855 | 11.8171 |
| Nauda un Ekvivalenti | 6.80665 | 10.7006 | 10.4958 | 10.1855 | 11.8171 |
| Īstermiņa Ieguldījumi | 0 | 0 | 0 | 0 | |
| Debitoru Parādu Kopsumma, Neto | 2.47679 | 2.06257 | 2.43774 | 2.72071 | 2.65874 |
| Accounts Receivable - Trade, Net | 2.39021 | 2.04995 | 2.42226 | 2.69423 | 2.65259 |
| Total Inventory | 2.12245 | 2.42086 | 2.66697 | 3.08997 | 3.43583 |
| Prepaid Expenses | 0.40315 | 0.34815 | 0.47501 | 0.26871 | 0.38739 |
| Other Current Assets, Total | 0.0008 | 0 | 0 | 0 | |
| Total Assets | 39.6215 | 43.7296 | 44.2315 | 44.4657 | 46.6995 |
| Property/Plant/Equipment, Total - Net | 27.6019 | 27.9906 | 27.9526 | 28.0027 | 28.2102 |
| Property/Plant/Equipment, Total - Gross | 39.7899 | 40.7931 | 41.3531 | 41.996 | 42.7809 |
| Accumulated Depreciation, Total | -12.1879 | -12.8025 | -13.4004 | -13.9933 | -14.5707 |
| Goodwill, Net | 0.09556 | 0.09556 | 0.09556 | 0.09556 | 0.09556 |
| Intangibles, Net | 0.09074 | 0.08597 | 0.08119 | 0.07642 | 0.07164 |
| Other Long Term Assets, Total | 0.02339 | 0.02539 | 0.0266 | 0.02612 | 0.023 |
| Total Current Liabilities | 2.09827 | 2.03218 | 2.16568 | 2.53447 | 2.3511 |
| Accounts Payable | 0.74319 | 0.53679 | 0.70338 | 0.74504 | 0.66207 |
| Accrued Expenses | 0.44569 | 0.5278 | 0.48164 | 0.776 | 0.49141 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.76752 | 0.77499 | 0.78253 | 0.81221 | 0.94728 |
| Other Current Liabilities, Total | 0.14187 | 0.19259 | 0.19813 | 0.20122 | 0.25034 |
| Total Liabilities | 11.7503 | 11.461 | 11.7696 | 11.8888 | 13.327 |
| Total Long Term Debt | 8.54383 | 8.34768 | 8.54975 | 8.32712 | 9.97774 |
| Long Term Debt | 8.54383 | 8.34768 | 8.54975 | 8.32712 | 9.97774 |
| Other Liabilities, Total | 1.10817 | 1.08116 | 1.05416 | 1.02716 | 0.99811 |
| Total Equity | 27.8712 | 32.2686 | 32.4619 | 32.5769 | 33.3725 |
| Common Stock | 0.7299 | 0.78142 | 0.78142 | 0.78142 | 0.78142 |
| Additional Paid-In Capital | 31.414 | 35.606 | 35.6515 | 35.6924 | 35.7501 |
| Retained Earnings (Accumulated Deficit) | -4.10171 | -3.96059 | -3.81283 | -3.73869 | -3.00303 |
| Treasury Stock - Common | -0.17102 | -0.15817 | -0.15817 | -0.15817 | -0.15598 |
| Total Liabilities & Shareholders’ Equity | 39.6215 | 43.7296 | 44.2315 | 44.4657 | 46.6995 |
| Total Common Shares Outstanding | 7.22084 | 7.74186 | 7.74186 | 7.74186 | 7.74286 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 0.50845 | -0.16815 | -2.32167 | -1.29559 | -1.02212 | -0.07829 |
| Nauda no Darbības | -0.3239 | 1.17582 | -0.3734 | 0.23351 | 1.31558 | 0.95417 |
| Nauda no Darbības | 0.78328 | 0.88533 | 1.50161 | 2.24832 | 2.32818 | 2.44204 |
| Amortization | 0.0191 | 0.0191 | 0.0191 | 0.0191 | 0.0191 | 0.0191 |
| Deferred Taxes | 0.23629 | -0.28481 | 0.46232 | 0.02468 | -0.01463 | 0 |
| Bezskaidras Naudas Preces | 0.10491 | 0.19143 | -0.33742 | 0.33259 | -0.52722 | 0.19383 |
| Cash Taxes Paid | 0.12358 | 0.00607 | 0.00422 | 0.00357 | 0.00458 | 0.00511 |
| Samaksātie Procenti Naudā | 0.15309 | 0.18654 | 0.40354 | 0.42096 | 0.48141 | 0.30868 |
| Izmaiņas Apgrozāmajā Kapitālā | -1.97593 | 0.53292 | 0.30266 | -1.0956 | 0.53226 | -1.62251 |
| Nauda no Ieguldījumu Darbībām | -4.42263 | -12.2735 | -1.79397 | -3.40336 | -2.56994 | -1.59736 |
| Kapitālie Izdevumi | -3.58635 | -17.7599 | -2.0299 | -1.39145 | -4.07254 | -2.60865 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -0.83628 | 5.48634 | 0.23592 | -2.01191 | 1.5026 | 1.01129 |
| Nauda no Darbībām ar Finansēšanu | 8.32355 | 9.74618 | 0.88962 | 6.94209 | 1.91101 | 3.87872 |
| Naudas Plūsma Finansēšanas Posteņos | -0.04673 | -0.0661 | -0.00197 | -0.05314 | 0.00227 | |
| Akciju Izsniegšana (Atkāpšanās), Neto | 8.50612 | 3.8179 | 0.09625 | 8.30344 | 0.00001 | 4.24472 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -0.13584 | 5.99438 | 0.79533 | -1.36135 | 1.96413 | -0.36827 |
| Neto Izmaiņas Naudā | 3.57702 | -1.35153 | -1.27776 | 3.77224 | 0.65664 | 3.23553 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -0.4413 | -0.30019 | -0.15243 | -0.07829 | 0.73567 |
| Cash From Operating Activities | -0.62355 | 0.10729 | 0.36628 | 0.95417 | 0.63854 |
| Cash From Operating Activities | 0.6147 | 1.23222 | 1.84561 | 2.44204 | 0.61685 |
| Amortization | 0.00478 | 0.00955 | 0.01433 | 0.0191 | 0.00478 |
| Deferred Taxes | 0 | 0 | 0 | 0 | |
| Non-Cash Items | 0.02927 | 0.05717 | 0.14958 | 0.19383 | 0.04908 |
| Cash Interest Paid | 0.07877 | 0.15742 | 0.23432 | 0.30868 | 0.07188 |
| Changes in Working Capital | -0.83098 | -0.89147 | -1.49081 | -1.62251 | -0.76783 |
| Cash From Investing Activities | 0.65668 | -0.22266 | -0.89408 | -1.59736 | -0.7965 |
| Capital Expenditures | -0.34932 | -1.22866 | -1.90406 | -2.60865 | -0.8075 |
| Other Investing Cash Flow Items, Total | 1.006 | 1.006 | 1.00998 | 1.01129 | 0.011 |
| Cash From Financing Activities | -0.17643 | 3.86598 | 4.07363 | 3.87872 | 1.78963 |
| Financing Cash Flow Items | 0.00227 | 0.00227 | 0.00227 | 0.00227 | -0.01883 |
| Issuance (Retirement) of Stock, Net | 0.01168 | 4.24472 | 4.24472 | 4.24472 | 0.00584 |
| Issuance (Retirement) of Debt, Net | -0.19038 | -0.38101 | -0.17337 | -0.36827 | 1.80262 |
| Net Change in Cash | -0.14329 | 3.75061 | 3.54582 | 3.23553 | 1.63167 |
| Cash Taxes Paid | 0.00513 | 0.00514 | 0.00511 | 0.00554 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Pessin (Norman H) | Individual Investor | 9.0828 | 703636 | 0 | 2022-04-14 | LOW |
| Rothschild (Jonathan E) | Individual Investor | 6.635 | 514003 | 0 | 2022-04-14 | LOW |
| Pessin (Sandra F) | Individual Investor | 5.1869 | 401819 | 0 | 2022-04-14 | |
| Brigham (Michael F) | Individual Investor | 2.785 | 215752 | 0 | 2022-04-14 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6633 | 206325 | 3596 | 2022-12-31 | LOW |
| Crabb (Joseph H) | Individual Investor | 1.8439 | 142845 | 0 | 2022-04-14 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.6199 | 125489 | -12097 | 2022-12-31 | HIGH |
| Pessin (Brian L) | Individual Investor | 1.4287 | 110682 | 0 | 2022-04-14 | LOW |
| Bleichroeder LP | Investment Advisor | 1.3114 | 101594 | 0 | 2022-12-31 | LOW |
| Cresset Asset Management, LLC | Investment Advisor/Hedge Fund | 1.2447 | 96426 | 0 | 2022-12-31 | LOW |
| Tomsche (David Scott) | Individual Investor | 1.2447 | 96426 | 2407 | 2022-09-12 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.9923 | 76874 | 2800 | 2022-12-31 | LOW |
| Shufro, Rose & Co., LLC | Investment Advisor | 0.8056 | 62408 | 0 | 2022-12-31 | |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.8025 | 62170 | 39591 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4916 | 38082 | -53 | 2022-12-31 | LOW |
| Overbrook Management Corporation | Investment Advisor | 0.4587 | 35532 | 0 | 2022-12-31 | LOW |
| Strategic Financial Services, Inc. | Investment Advisor | 0.4002 | 31000 | 0 | 2022-12-31 | LOW |
| Perritt Capital Management, Inc. | Investment Advisor | 0.3873 | 30000 | -6494 | 2022-12-31 | LOW |
| Hightower Advisors, LLC | Investment Advisor | 0.2756 | 21354 | 0 | 2022-12-31 | LOW |
| Cunningham (David S) | Individual Investor | 0.2065 | 16000 | 1000 | 2022-06-13 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group 500000+
Tirgotāji
92000+
Ikmēneša aktīvie klienti
$53000000+
Ikmēneša ieguldījumu apjoms
$30000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
ImmuCell Company profile
Par ImmuCell
ImmuCell Corporation ir dzīvnieku veselības uzņēmums. Uzņēmums nodarbojas ar tādu produktu izstrādi, iegādi, ražošanu un pārdošanu, kas uzlabo piena un gaļas liellopu veselību un produktivitāti. Uzņēmums ražo un tirgo First Defense produktu līniju, kas paredzēta jaundzimušo piena un liellopu teļu skudru profilaksei. Uzņēmums ir paplašinājis šo līniju ar pieciem dažādiem produktiem, kuru sastāvs ir vērsts pret E. coli un koronavīrusa patogēniem, kā arī pret E. coli, koronavīrusa un rotavīrusa patogēniem. Tās Tri-Shield First Defense produktu līnijas paplašinājums ir teļa līmeņa pasīvo antivielu produkts, kas nodrošina tūlītēju imunitāti pret E. coli, koronavīrusu un rotavīrusu. Šī produktu līnija nodrošina tūlītēju imunitāti jaundzimušajiem teļiem. Uzņēmums ir iesaistījies Re-Tain, nizīna preparāta pret subklīnisko mastītu slaucamām slaucamām govīm, izstrādē. Uzņēmuma produkti samazina tradicionālo antibiotiku lietošanu produktīvajiem dzīvniekiem.
| Industry: | Biotechnology & Medical Research (NEC) |
56 Evergreen Drive
04103
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com